National Institute on Drug Abuse Intramural Research Program, Baltimore, MD (SWS; KES; DHE); Department of Pharmacology, University of North Carolina-Chapel Hill (DPE); Department of Biobehavioral Health, State College, The Pennsylvania State University, PA (SWS); Department of Anesthesiology, Perioperative & Pain Medicine, School of Medicine, Stanford University, Palo Alto, CA (NV).
Send correspondence to Samuel W. Stull, BA, Department of Biobehavioral Health, The Pennsylvania State University, Biobehavioral Health Building, University Park, PA, 16802. E-mail: [email protected]; Kirsten Smith, PhD, National Institute on Drug Abuse, Intramural Research Program, Clinical Pharmacology and Therapeutics Research Branch, 251 Bayview Blvd. Suite 200, Room 01B340, Baltimore, Maryland, 21224. E-mail: [email protected].
Received 21 October, 2020
Accepted 18 April, 2021
SWS is supported by a National Science Foundation Graduate Research Fellowship under grant No. DGE1255832. KES and DHE are supported by the Intramural Research Program NIH/NIDA. NAV was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number T32DA035165. Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation or the National Institutes of Health.
Samuel W. Stull and Kirsten E. Smith contributed equally.
The authors report no conflicts of interest.
